Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma

Yitian Wang; Jian Zhu; Wei Yu; Junjie Wang; Kaishun Xia; Chengzhen Liang; Huimin Tao

doi:10.1016/j.jbo.2018.100214

Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma

J Bone Oncol. 2018 Dec 26:21:100214. doi: 10.1016/j.jbo.2018.100214. eCollection 2020 Apr.

Authors

Yitian Wang^{1

2}, Jian Zhu^{1

2}, Wei Yu^{1

2}, Junjie Wang^{1

2}, Kaishun Xia^{1

2}, Chengzhen Liang^{1

2}, Huimin Tao^{1

2}

Affiliations

¹ Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, #88 Jie Fang Road, Hangzhou, 310009, Zhejiang, PR China.
² Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China.

Abstract

Human γδ T cells have displayed their potential in cancer immunity through efficient tumor killing activities. Besides, they are also known for their capacity of antigen presentation. How to improve γδ T cells' immunotherapeutic effect as the cell vaccine is still a great challenge. Herein, we explore the human γδ T cells and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma. The fusion cell vaccine was prepared by chemical fusion between human γδ T cells and inactive osteosarcoma Saos-2 cells. The fusion process was confirmed by microscopy observation, and flow cytometry analysis further validated the antigen presenting functions of the fusion cells. Moreover, the immunotherapeutic potential of the fusion cells was then verified via cytotoxicity assay and cytokine release detection. Our study provided novel immunotherapeutic strategy for patients with osteosarcoma, which merits further practice in the near future.

Keywords: Antigen presenting cells; Fusion cells; Immunotherapy; Osteosarcoma; Vaccine; γδ T cells.